Biotech Values

[oc631]

The inclusion of genotype-1 is a mild surprise

The inclusion of GT1 patients in this Sofo/Riba study is nothing more than an shallow attempt to suggest longer durations have wider merit. Since GS-5885 is a safe and tolerable drug which allows for 12-week dosing (or less) in GT1 why would GILD push out studies to 16 and 24-weeks? I think GILD should make sure their combo works sufficiently well in the absence of ribavirin before they consider dropping the NS5A.